Apr 28, 2026 08:53PM
Apr 28, 2026 08:53PM
Apr 14, 2026 08:11PM
Apr 14, 2026 08:10PM
Apr 10, 2026 04:09PM
Apr 8, 2026 09:07AM
Apr 7, 2026 11:35PM Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Mar 17, 2026 07:19PM
Mar 11, 2026 07:21PM
Feb 26, 2026 07:42PM
Feb 11, 2026 06:27PM
Jan 28, 2026 06:54PM
Jan 26, 2026 06:45PM
Jan 18, 2026 07:01PM FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
Jan 8, 2026 06:46PM
Jan 1, 2026 06:02PM
Jan 1, 2026 06:02PM
Dec 29, 2025 06:57PM
Dec 11, 2025 06:22PM
Dec 3, 2025 06:10PM
Nov 24, 2025 06:39PM Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
Nov 20, 2025 06:32PM
Nov 4, 2025 06:40PM
Oct 19, 2025 07:48PM
Oct 6, 2025 07:24PM
Oct 2, 2025 09:04PM
Sep 26, 2025 01:49AM
Sep 14, 2025 09:18PM Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
Sep 3, 2025 09:47PM
Aug 28, 2025 08:24PM
Jul 17, 2025 08:38PM
Jun 30, 2025 08:36PM
Jun 11, 2025 09:24PM
May 14, 2025 11:36PM
May 14, 2025 10:57PM FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
Apr 29, 2025 08:53PM
Apr 28, 2025 07:44PM
Apr 3, 2025 06:58PM
Apr 2, 2025 07:15PM
Mar 30, 2025 07:39PM
Mar 13, 2025 07:42PM
Mar 6, 2025 06:54PM Mesoblast Added to S&P/ASX 200 INDEX
Feb 26, 2025 05:30PM
Feb 25, 2025 06:13PM
Feb 23, 2025 06:33PM
Feb 13, 2025 06:37PM
Jan 30, 2025 07:11PM
Jan 30, 2025 06:20PM
Dec 18, 2024 07:08PM Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
Dec 4, 2024 06:32PM

322,248 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All